Evidence brief · Supplement
Noopept for Cognition
Evidence grade D — Limited Western data
- Overall grade
- Grade D
- Last revised
- 1
- graded outcome
- 0
- references listed
Assembled by the app from other entries in this library. It adds no evidence of its own — follow the links to the entries it draws on.
1 at grade D — 1 graded row
What is known
Each outcome with its grade (how strong the evidence is, A to D), the size of the effect where the entry records one, and how often studies agree.
- CognitionEvidence grade D
Limited Western data
Unclearlow
What is uncertain
Read off the same rows as above. Nothing here is added that the entry does not itself record.
- Thin evidence: Cognition (grade D).
The evidence in words
The verdict
For cognition, Noopept earns evidence grade D (unclear effect, low consistency) — the evidence does not support the claim. Limited Western data
How it might work
Proposed to raise BDNF/NGF and modulate glutamate; largely characterized in Russian and animal research.
How to use it
Safety & cautions
Generally tolerated at low doses; long-term safety uncharacterized.
Bottom line
Heavily hyped online with thin independent evidence. Not established.
Goes with
- NoopeptRead the full Noopept monographEvidence grade D
Related reading
Entries that share this one's tags or conditions.
- Oxiracetam for CognitionEvidence grade D — SparseEvidence grade D
- Methylene BlueA century-old dye and drug repurposed as a low-dose mitochondrial nootropic — real pharmacology, serious MAOI-level interactions.Evidence grade C
- Methylene Blue for Memory / brain metabolismEvidence grade C — Low-dose, small trialsEvidence grade C
- Noopept: side effects, safety & interactionsGenerally tolerated at low doses; long-term safety uncharacterized.Evidence grade D
Sources
This entry lists no references of its own — it is assembled from the entries it links to, whose sources are on their pages.
Last revised . A grade is this entry's reading of the evidence, not medical advice.